{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:14:06Z","timestamp":1781763246361,"version":"3.54.5"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/wnf.0000000000000091","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T21:35:00Z","timestamp":1436650500000},"page":"132-134","source":"Crossref","is-referenced-by-count":69,"title":["Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Antoniya","family":"Todorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.","volume":"23","author":"OSullivan","year":"2009","journal-title":"CNS Drugs"},{"issue":"Pt 5","key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a 11C raclopride PET study.","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission.","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol"},{"issue":"11","key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00415-012-6798-6","article-title":"Selecting deep brain stimulation or infusion therapies in advanced Parkinsons disease: an evidence-based review.","volume":"60","author":"Volkmann","year":"2013","journal-title":"J Neurol"},{"issue":"8","key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinsons disease with motor fluctuations: a multicentre study.","volume":"23","author":"Garcia Ruiz","year":"2008","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"R7-3-20210203","first-page":"S44","article-title":"An audit of apomorphine in the management of complex idiopathic Parkinsons disease in Ireland.","volume":"27","author":"Magennis","year":"2012","journal-title":"Mov Disord"},{"issue":"3","key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinsons disease: from clinical and neuropsychological characterisation to management and long-term outcome.","volume":"85","author":"Cilia","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinsons disease.","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov Disord"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinsons disease compared to conventional therapy: a real-life study of non-motor effect.","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J Parkinsons Dis"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNF.0b013e3182613dea","article-title":"Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects.","volume":"35","author":"Reddy","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinsons disease: the NMSQuest Study.","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov Disord"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of a questionnaire for impulsive-compulsive disorders in Parkinsons disease (QUIP).","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"issue":"Suppl","key":"R14-3-20210203","first-page":"161","article-title":"European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD.","volume":"27","author":"Rizos","year":"2012","journal-title":"Mov Disord"},{"issue":"1","key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinsons disease: a double-blind, randomised, placebo-controlled study (RECOVER).","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","article-title":"A reassessment of risk and benefits of dopamine agonists in Parkinsons disease.","volume":"8","author":"Antonini","year":"2009","journal-title":"Lancet Neurol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:10:15Z","timestamp":1620976215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201507000-00003"}},"subtitle":["Clinical Experience After 3 Years\u2019 Follow-up"],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000091","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}